New PET tracer could spot Hard-to-Find neuroendocrine cancers

NCT ID NCT07132645

Recruiting now Diagnosis Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial is testing a radioactive tracer called FAPI-04 to see how well it lights up high-grade neuroendocrine tumors on PET/CT scans. The study will enroll 30 adults with these aggressive tumors to measure where the tracer goes in the body and how much it accumulates in cancer compared to normal tissues. The goal is to determine if this imaging method could help doctors better detect and monitor these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium Ga 68-DOTA-FAPI-04 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a more accurate imaging method for detecting high-grade neuroendocrine tumors, potentially improving diagnosis and treatment planning.
What could go wrong: This is a very early (Phase 1) exploratory study with only 30 participants. It is designed to see where the tracer goes in the body, not to prove it improves outcomes. The tracer may not reliably distinguish tumors from normal tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMOR

Contacts and locations

Locations

University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.